HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System harnessing Nano-Pulse Stimulation™ (NPS™) technology, today announced podium presentations of its NPS technology at two premier medical aesthetics meetings:
- “A histological analysis of facial tissue in response to NPS treatment” will be featured at the Annual Meeting of the American Academy Facial Plastic and Reconstructive Surgery in San Diego, CA, on October 3, 2019 at 2:20pm.
- An overview of NPS technology will be delivered at the 14th Annual “Laser & Aesthetic Skin Therapy: What’s the Truth?” organized by Harvard Medical School in Boston, MA on October 5, 2019 at 8:30am.
“It is a privilege to introduce my facial plastic surgery colleagues to this groundbreaking Nano-Pulse Stimulation technology to clear benign lesions,” said James Newman, MD, Chief of Plastic Surgery at Premier Plastic Surgery Clinics in the San Francisco Bay Area, CA. “I look forward to presenting our histological analysis of pre-facelift tissue that guided our study to establish a safe range of energy levels on facial skin that also showed a damaging effect on cellular components of sebaceous glands. Based on the safety validated by this range of energy settings, we then were able to successfully demonstrate high clearance rates of facial sebaceous hyperplasia lesions.”
At the prestigious Harvard Medical School meeting, Nano-Pulse Stimulation technology will be highlighted as one of four new and emerging treatments. Co-chair Mathew Avram, MD, Associate Professor of Dermatology, Faculty Director for Dermatology, Laser & Cosmetic Surgery Training at Harvard Medical School, will present the science of NPS technology as a cutting-edge topic at this highly acclaimed meeting. Dr. Avram’s lecture will also offer a glimpse into the clinical future of this novel cellular approach to clearing unwanted benign and malignant lesions.
“We are delighted and honored that key opinion leaders have chosen to present our novel Nano-Pulse Stimulation technology at renowned scientific meetings of the world’s leading dermatologists and facial plastic surgeons,” said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. “This recognition drives our commercial commitment to bring the clinical benefits of our CellFX procedure to physicians and their patients who seek better outcomes and satisfying experiences when it comes to lesion clearance.”
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that improves and potentially extends the lives of patients. The CellFX System is the first planned commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of high amplitude electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials. The CellFX System is preparing to launch in 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. As part of the customer experience, the Company is offering a utilization-based revenue model and easy-access customer portal offering a suite of services. CellFX procedures offer customer value across an expanding spectrum of clinical applications. The initial commercial use will be in the clearance of common and difficult to treat skin lesions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of FDA filings or approvals, the mechanism of action of NPS treatments, current and planned future clinical studies, other matters related to its pipeline of product candidates, future financial performance and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.